ATE502642T1 - Kombinationen für die behandlung von immun- entzündlichen erkrankungen - Google Patents

Kombinationen für die behandlung von immun- entzündlichen erkrankungen

Info

Publication number
ATE502642T1
ATE502642T1 AT02800923T AT02800923T ATE502642T1 AT E502642 T1 ATE502642 T1 AT E502642T1 AT 02800923 T AT02800923 T AT 02800923T AT 02800923 T AT02800923 T AT 02800923T AT E502642 T1 ATE502642 T1 AT E502642T1
Authority
AT
Austria
Prior art keywords
immuno
combinations
treatment
inflammatory diseases
inflammatory
Prior art date
Application number
AT02800923T
Other languages
English (en)
Inventor
Curtis Keith
Alexis Borisy
Grant Zimmermann
Edward Jost-Price
Palaniyandi Manivasakam
Nicole Hurst
Michael Foley
Original Assignee
Zalicus Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23277540&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE502642(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Zalicus Inc filed Critical Zalicus Inc
Application granted granted Critical
Publication of ATE502642T1 publication Critical patent/ATE502642T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT02800923T 2001-10-05 2002-10-04 Kombinationen für die behandlung von immun- entzündlichen erkrankungen ATE502642T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32767401P 2001-10-05 2001-10-05
PCT/US2002/031866 WO2003030823A2 (en) 2001-10-05 2002-10-04 Combinations for the treatment of immunoinflammatory disorders

Publications (1)

Publication Number Publication Date
ATE502642T1 true ATE502642T1 (de) 2011-04-15

Family

ID=23277540

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02800923T ATE502642T1 (de) 2001-10-05 2002-10-04 Kombinationen für die behandlung von immun- entzündlichen erkrankungen

Country Status (26)

Country Link
US (3) US7253155B2 (de)
EP (2) EP1448205B1 (de)
JP (1) JP2005508346A (de)
KR (2) KR100917082B1 (de)
CN (1) CN100400044C (de)
AR (1) AR036741A1 (de)
AT (1) ATE502642T1 (de)
AU (1) AU2002334870B2 (de)
BR (1) BR0213100A (de)
CA (1) CA2461946C (de)
DE (1) DE60239558D1 (de)
DK (1) DK1448205T3 (de)
ES (1) ES2363334T3 (de)
HR (1) HRP20040388A2 (de)
IL (1) IL161267A0 (de)
IS (1) IS7202A (de)
MX (1) MXPA04003266A (de)
NO (1) NO20041386L (de)
NZ (1) NZ532310A (de)
PL (1) PL370764A1 (de)
PT (1) PT1448205E (de)
RU (1) RU2322984C2 (de)
SI (1) SI1448205T1 (de)
TW (1) TWI247605B (de)
WO (1) WO2003030823A2 (de)
ZA (1) ZA200402955B (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1411938B1 (de) * 2001-07-02 2005-07-06 Tas, Sinan Verwendung von cyclopamine zur Herstellung eines Arzneimittels zur Behandlung von Psoriasis
MXPA04003266A (es) * 2001-10-05 2004-07-08 Combinatorx Inc Combinaciones para el tratamiento de desodrdenes inmuno-inflamatorios.
ES2343411T3 (es) 2003-03-26 2010-07-30 Synergy Biosystems Ltd. Procedimientos para identificar agentes biologicamente activos y combinaciones sinergicas.
US20050112199A1 (en) * 2003-09-24 2005-05-26 Mahesh Padval Therapeutic regimens for administering drug combinations
TW200517114A (en) * 2003-10-15 2005-06-01 Combinatorx Inc Methods and reagents for the treatment of immunoinflammatory disorders
AU2005235369B2 (en) * 2004-04-22 2010-11-11 Acucort Ab Pharmaceutical compositions for acute glucocorticoid therapy
US8907153B2 (en) * 2004-06-07 2014-12-09 Nuvo Research Inc. Adhesive peel-forming formulations for dermal delivery of drugs and methods of using the same
US20070196452A1 (en) * 2004-06-07 2007-08-23 Jie Zhang Flux-enabling compositions and methods for dermal delivery of drugs
US7799331B2 (en) 2005-08-04 2010-09-21 Taro Pharmaceutical North America, Inc. Oral suspension of prednisolone acetate
CA2652773A1 (en) * 2006-05-22 2007-12-06 Combinatorx, Incorporated Methods and compositions for the treatment of diseases or conditions associated with increased c-reactive protein, interleukin-6, or interferon-gamma levels
US20070299017A1 (en) * 2006-06-23 2007-12-27 Kanter Mitchell M Compositions for lowering blood serum cholesterol and use in foods, beverages, and health supplements
KR20250002752A (ko) 2007-07-23 2025-01-07 더 차이니즈 유니버시티 오브 홍콩 대규모 병렬 게놈 서열분석을 이용한 태아 염색체 이수성의 진단 방법
US12180549B2 (en) 2007-07-23 2024-12-31 The Chinese University Of Hong Kong Diagnosing fetal chromosomal aneuploidy using genomic sequencing
CA2737131A1 (en) * 2007-09-19 2009-03-26 Zalicus Inc. Therapeutic regimens for the treatment of immunoinflammatory disorders
JP2011506607A (ja) * 2007-12-17 2011-03-03 ザリカス インコーポレイティッド 免疫炎症性障害の処置のための治療法
WO2009144720A1 (en) * 2008-05-27 2009-12-03 Pluristem Ltd. Methods of treating inflammatory colon diseases
US20130338127A1 (en) * 2010-05-06 2013-12-19 Nuvo Research Inc. Triamcinolone acetonide formulations for treating dermatitis and psoriasis
MD480Z (ro) * 2011-07-07 2012-09-30 Elvira Andon Metoda de tratament al colitei ulceroase nespecifice acute
US9892230B2 (en) 2012-03-08 2018-02-13 The Chinese University Of Hong Kong Size-based analysis of fetal or tumor DNA fraction in plasma
US10364467B2 (en) 2015-01-13 2019-07-30 The Chinese University Of Hong Kong Using size and number aberrations in plasma DNA for detecting cancer
JP6925272B2 (ja) * 2015-01-28 2021-08-25 リアルイン ライフ サイエンス リミテッド ＰＰＡＲγ発現および核転座を促進する化合物およびそれの治療的使用
US20180289708A1 (en) * 2015-10-15 2018-10-11 Moshe Rogosnitzky Low dose oral dipyridamole compositions and uses thereof
CN111346228B (zh) * 2018-12-21 2022-01-14 广州市妇女儿童医疗中心 胃肠道疾病的免疫机制及治疗药物
CN114432451B (zh) * 2018-12-21 2024-02-09 广州市妇女儿童医疗中心 胃肠道疾病的免疫机制及治疗药物
EP3972603B1 (de) 2019-05-23 2024-09-04 Novartis AG Methoden zur behandlung von sjögren-syndrom mit einem hemmer von bruton-kinase
CN113456618A (zh) * 2020-03-31 2021-10-01 天津金耀集团有限公司 一种复方双嘧达莫的吸入制剂及其制备方法
EP4427752A1 (de) * 2023-03-09 2024-09-11 Fundacion Instituto De Investigacion Sanitaria Fundacion Jimenez Diaz Dipyridamol als neue therapie für muskelmyogeneseerkrankungen und entzündliche arthritis

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US579476A (en) * 1897-03-23 Sash-holder
US3031450A (en) 1959-04-30 1962-04-24 Thomae Gmbh Dr K Substituted pyrimido-[5, 4-d]-pyrimidines
US4034087A (en) * 1973-12-17 1977-07-05 The Regents Of The University Of Michigan Pharmaceutical composition and process of treatment
US4107306A (en) * 1973-01-16 1978-08-15 The Regents Of The University Of Michigan Process for treating proliferative skin disease
DD119586A5 (de) 1973-12-21 1976-05-05
US3934036A (en) * 1975-01-23 1976-01-20 Kyorin Seiyaku Kabushiki Kaisha N-benzenesulfonyl-β-alanine hydrazide useful as an immunosuppressive agent
FR2470599A1 (fr) 1979-12-07 1981-06-12 Panoz Donald Perfectionnements apportes aux procedes de preparation de formes galeniques a action retard et a liberation programmee et formes galeniques de medicaments ainsi obtenus
DE3000979A1 (de) * 1980-01-12 1981-07-23 Dr. Karl Thomae Gmbh, 7950 Biberach Neue dipyridamol-retardformen und verfahren zu ihrer herstellung
BG36086A1 (en) * 1982-01-19 1984-09-14 Glbov Method for inducing interferon
US4387217A (en) * 1982-04-07 1983-06-07 Basf Wyandotte Corporation High foaming iodophors
US4879119A (en) * 1984-02-21 1989-11-07 Yamanouchi Pharmaceutical Co., Ltd. Patch
JPS60174716A (ja) * 1984-02-21 1985-09-09 Yamanouchi Pharmaceut Co Ltd パツチ剤
US4554271A (en) * 1984-02-24 1985-11-19 The Upjohn Company Use of high doses of derivatives of 6α-methylprednisolone for the acute treatment of stroke syndrome
DE3627423A1 (de) * 1986-08-13 1988-02-18 Thomae Gmbh Dr K Arzneimittel enthaltend dipyridamol oder mopidamol und o-acetylsalicylsaeure bzw. deren physiologisch vertraegliche salze, verfahren zu ihrer herstellung und ihre verwendung zur bekaempfung der thrombusbildung
AU618517B2 (en) * 1986-12-23 1992-01-02 Eugene J. Van Scott Additives enhancing topical actions of therapeutic agents
EP0303713B2 (de) 1987-02-23 1997-07-30 Shiseido Company Limited Perkutaner absorptionspromotor und dermatologische zusammensetzung für externe anwendung
US5668116A (en) * 1987-03-19 1997-09-16 Anthropharm Pty. Limited Anti-inflammatory compounds and compositions
WO1989010122A1 (en) 1988-04-27 1989-11-02 Yale University Compositions and methods for treating cutaneous hyperproliferative disorders
US5242921A (en) * 1988-04-27 1993-09-07 Yale University Compositions and methods for treating cutaneous hyperproliferative disorders
WO1992016226A1 (en) 1991-03-19 1992-10-01 Smithkline Beecham Corporation Il-1 inhibitors
US5270047A (en) * 1991-11-21 1993-12-14 Kauffman Raymond F Local delivery of dipyridamole for the treatment of proliferative diseases
US5474765A (en) * 1992-03-23 1995-12-12 Ut Sw Medical Ctr At Dallas Preparation and use of steroid-polyanionic polymer-based conjugates targeted to vascular endothelial cells
EG20321A (en) * 1993-07-21 1998-10-31 Otsuka Pharma Co Ltd Medical material and process for producing the same
US5428040A (en) 1993-08-31 1995-06-27 The Du Pont Merck Pharmaceutical Company Carbocyclic fused-ring quinolinecarboxylic acids useful as immunosuppressive agents
TW249754B (de) * 1993-10-26 1995-06-21 Alpha I Biomedicals Inc
GB2292079B (en) * 1994-08-12 1998-07-15 Flexpharm Ltd Coated prednisolone preparation for the treatment of inflamatory bowel disease
DE4430128A1 (de) * 1994-08-25 1996-02-29 Hoechst Ag Kombinationspräparat mit immunsuppressiven, kardiovaskulären und cerebralen Wirkungen
FR2732223B1 (fr) * 1995-03-30 1997-06-13 Sanofi Sa Composition pharmaceutique pour administration transdermique
WO1996036611A1 (en) 1995-05-19 1996-11-21 Chiroscience Limited 3,4-disubstituted-phenylsulphonamides and their therapeutic use
US6265427B1 (en) * 1995-06-07 2001-07-24 The Proctor & Gamble Company Pharmaceutical composition for the method of treating leukemia
US6172066B1 (en) * 1996-05-16 2001-01-09 Synaptic Pharmaceutical Corporation Dihydropyrimidines and uses thereof
US6235706B1 (en) * 1996-09-18 2001-05-22 Merck & Co., Inc. Combination therapy for reducing the risks associated with cardiovascular disease
US5874437A (en) * 1996-11-01 1999-02-23 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
JP2001504457A (ja) 1996-11-01 2001-04-03 ニトロメド インコーポレーテッド ニトロソ化およびニトロシル化ホスホジエステラーゼ阻害剤化合物、組成物及びその使用法
US6331543B1 (en) * 1996-11-01 2001-12-18 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use
US5958926A (en) * 1996-11-01 1999-09-28 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
US5792476A (en) * 1996-12-19 1998-08-11 Abigo Medical Ab Sustained release glucocorticoid pharmaceutical composition
EP0979096B1 (de) * 1997-02-15 2003-05-14 Millennium Pharmaceuticals, Inc. Behandlung von infarkten durch inhibierung von nf-kappab
CN1269722A (zh) * 1997-03-18 2000-10-11 Basf公司 调节对皮质类固醇反应的方法及组合物
US6054487A (en) * 1997-03-18 2000-04-25 Basf Aktiengesellschaft Methods and compositions for modulating responsiveness to corticosteroids
ES2131463B1 (es) * 1997-04-08 2000-03-01 Lilly Sa Derivados de ciclopropilglicina con propiedades farmaceuticas.
WO1998055142A1 (en) 1997-06-05 1998-12-10 Eli Lilly And Company Methods for treating thrombotic disorders
EP1036561A1 (de) 1997-10-01 2000-09-20 Flemington Pharmaceutical Corporation Nichtpolare Spray zur bukkalen Anwendung
US20030077229A1 (en) 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing cardiovascular or renal drugs
US6372254B1 (en) * 1998-04-02 2002-04-16 Impax Pharmaceuticals Inc. Press coated, pulsatile drug delivery system suitable for oral administration
WO1999062537A1 (en) * 1998-06-04 1999-12-09 The Rockefeller University Methods and agents for modulating the immune response and inflammation involving monocyte and dendritic cell membrane proteins
US6184226B1 (en) 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
CN1246335A (zh) 1998-08-28 2000-03-08 冀聪韬 一种用于治疗皮肤病药物的制作方法
US6602521B1 (en) * 1998-09-29 2003-08-05 Impax Pharmaceuticals, Inc. Multiplex drug delivery system suitable for oral administration
US6677326B2 (en) * 1999-03-15 2004-01-13 Arakis, Ltd. Corticosteroid formulation comprising less than 2.5 mg prednisolone for once daily administration
US6383471B1 (en) 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
WO2001002497A1 (en) 1999-06-30 2001-01-11 Beltran, German Cuevas Process and product for rendering a substance flame resistant
US7358056B1 (en) * 1999-08-30 2008-04-15 Signal Pharmaceuticals Methods for modulating signal transduction mediated by TGF-β and related proteins
AU7604400A (en) * 1999-09-21 2001-04-24 Emory University Methods and compositions for treating platelet-related disorders using mpl pathway inhibitory agents
CA2386457A1 (en) * 1999-10-06 2001-04-12 Basf Aktiengesellschaft Inhibitors of the endothelin signalling pathway and .alpha.v.beta.3 integrin receptor antagonists for combination therapy
EP1093814A1 (de) * 1999-10-22 2001-04-25 Boehringer Ingelheim Pharma KG Verwendung von Dipyridamole oder Mopidamol zur Herstellung eines Medikaments für die Behandlung und Vorbeugung von fibrinabhängigen Mikrozirkulationstörungen
AU1657001A (en) 1999-11-15 2001-05-30 Smithkline Beecham Corporation Carvedilol methanesulfonate
WO2001047572A2 (en) * 1999-12-29 2001-07-05 Advanced Cardiovascular Systems, Inc. Device and active component for inhibiting formation of thrombus-inflammatory cell matrix
US6363471B1 (en) * 2000-01-03 2002-03-26 Advanced Micro Devices, Inc. Mechanism for handling 16-bit addressing in a processor
US20020006435A1 (en) 2000-01-27 2002-01-17 Samuels Paul J. Transdermal anesthetic and vasodilator composition and methods for topical administration
DE10012555A1 (de) * 2000-03-15 2001-09-20 Merck Patent Gmbh Glucocorticoide in einer Modified Release-Formulierung
WO2001092273A2 (en) * 2000-05-30 2001-12-06 Guilford Pharmaceuticals Inc. Benzenedicarboxylic acid derivatives
WO2002022127A1 (en) 2000-09-13 2002-03-21 Isis Innovation Limited Use of phosphodiesterase inhibitors for the treatment of anorectal disorders
IL140537A0 (en) * 2000-12-25 2002-02-10 Hadasit Med Res Service Educated nk t cells and their uses in the treatment of immune-related disorders
WO2002069905A2 (en) * 2001-03-02 2002-09-12 Bristol-Myers Squibb Company Co-administration of melanocortin receptor agonist and phosphodiesterase inhibitor for treatment of cyclic-amp associated disorders
US6759058B1 (en) 2001-04-25 2004-07-06 Western Center For Drug Development College Of Pharmacy Western University Of Health Sciences Enteric-coated proliposomal formulations for poorly water soluble drugs
US6960357B2 (en) 2001-05-25 2005-11-01 Mistral Pharma Inc. Chemical delivery device
GB0119848D0 (en) 2001-08-15 2001-10-10 Univ Sheffield Delayed and sustained drug release
MXPA04003266A (es) 2001-10-05 2004-07-08 Combinatorx Inc Combinaciones para el tratamiento de desodrdenes inmuno-inflamatorios.
AU2002346472A1 (en) 2001-11-20 2003-06-10 Advanced Inhalation Research, Inc. Particulate compositions for improving solubility of poorly soluble agents
DE10312234A1 (de) * 2002-03-20 2003-12-18 Lg Electronics Inc Betriebssteuervorrichtung und -verfahren für einen Linearkompressor
US20040180812A1 (en) * 2002-12-13 2004-09-16 Technology Center Methods of treating and preventing proliferative disease
AU2003300469A1 (en) 2002-12-31 2004-07-29 Larry L. Augsburger Methods for making pharmaceutical dosage forms containing active cushioning components
JP2006516593A (ja) 2003-02-07 2006-07-06 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｍｍｐ−９依存性疾患の治療及び予防のためのジピリダモール又はモピダモールの使用
US20050058688A1 (en) * 2003-02-22 2005-03-17 Lars Boerger Device for the treatment and prevention of disease, and methods related thereto
WO2005020933A2 (en) 2003-09-02 2005-03-10 University Of South Florida Nanoparticles for drug-delivery
TW200517114A (en) 2003-10-15 2005-06-01 Combinatorx Inc Methods and reagents for the treatment of immunoinflammatory disorders
EP1999626A4 (de) 2006-01-26 2009-11-25 Combinatorx Inc Verfahren, zusammensetzungen und kits zur behandlung von skelettmuskelkrankheiten und damit assoziierten symptomen
EP2387994A1 (de) 2006-01-27 2011-11-23 Eurand, Inc. Arzneimittelabgabesysteme mit einem schwachen Basisarzneimittel und organischen Säuren
CA2644889A1 (en) 2006-03-07 2007-09-13 Combinatorx, Incorporated Compositions and methods for the treatment of immunoinflammatory disorders

Also Published As

Publication number Publication date
KR20070100400A (ko) 2007-10-10
CN1599613A (zh) 2005-03-23
WO2003030823A3 (en) 2003-07-03
PT1448205E (pt) 2011-07-05
RU2004113551A (ru) 2005-02-27
EP1448205A2 (de) 2004-08-25
CN100400044C (zh) 2008-07-09
US7253155B2 (en) 2007-08-07
MXPA04003266A (es) 2004-07-08
TWI247605B (en) 2006-01-21
DE60239558D1 (de) 2011-05-05
NO20041386L (no) 2004-05-11
EP2279742A3 (de) 2011-04-20
KR100917082B1 (ko) 2009-09-15
US20110223621A1 (en) 2011-09-15
PL370764A1 (en) 2005-05-30
DK1448205T3 (da) 2011-12-12
JP2005508346A (ja) 2005-03-31
CA2461946A1 (en) 2003-04-17
AU2002334870B8 (en) 2003-04-22
KR100824491B1 (ko) 2008-04-22
AR036741A1 (es) 2004-09-29
US7915265B2 (en) 2011-03-29
BR0213100A (pt) 2004-11-30
HK1076387A1 (zh) 2006-01-20
KR20050033520A (ko) 2005-04-12
EP1448205B1 (de) 2011-03-23
RU2322984C2 (ru) 2008-04-27
EP2279742A2 (de) 2011-02-02
IL161267A0 (en) 2004-09-27
US20060234991A1 (en) 2006-10-19
CA2461946C (en) 2010-01-12
US20030119786A1 (en) 2003-06-26
AU2002334870B2 (en) 2007-10-04
HRP20040388A2 (en) 2004-10-31
NZ532310A (en) 2007-02-23
ZA200402955B (en) 2005-04-19
WO2003030823A2 (en) 2003-04-17
EP1448205A4 (de) 2007-01-03
ES2363334T3 (es) 2011-08-01
IS7202A (is) 2004-03-31
SI1448205T1 (sl) 2011-07-29

Similar Documents

Publication Publication Date Title
DE60239558D1 (de) Kombinationen für die behandlung von immun-entzündlichen erkrankungen
DE60218493D1 (de) Substituierte 7-aza-ä2.2.1übicycloheptane für die behandlung von krankheiten
ATE551340T1 (de) Azabicyclisch- substituierte annelierte heteroaryl-verbinungen für die behandlung von krankheiten
ATE439844T1 (de) Kombinationen für die behandlung entzündlicher erkrankungen
ATE374196T1 (de) Dihydrobenzodiazepin-2-on-derivative für die behandlung von neurologischen erkrankungen
ATE441417T1 (de) Benzoädüazepinderivate für die behandlung von neurologischen krankheiten
DE60124576D1 (de) Verbindungen verwendbar für die behandlung von entzündungskrankheiten
DE69927823T2 (de) Hydrogel für die therapeutische behandlung von aneurysmas
ATE396202T1 (de) Lang wirkendes glucagon-ähnliches peptid-2 für die behandlung von gastrointestinalen krankheiten und störungen
DE60325498D1 (de) 1-acyl-pyrrolidin-derivate für die behandlung von viralen infektionen
DE60108754D1 (de) Substituierte bizyklische derivate für die behandlung von unnormalem zellwachstum
DE60124302D1 (de) Thiazolderivate zur behandlung von ppar-lierte krankheiten
ATE286895T1 (de) Sulfonyl-pyrrolidinderivate geeignet für die behandlung von neurologischen krankheiten
DE50214540D1 (de) Stanz bei der behandlung von wunden
DE60239218D1 (de) Synergistische zusammensetzungen für die behandlung von saatgut
DE60231107D1 (de) Tetrahydro-pyrazinoä1,2-aüindole für die behandlung von krankheiten des zentralnervensystems
DE60236218D1 (de) CCR5 Antagonisten verwendbar für die Behandlung von Aids
DE60204466D1 (de) Integrinhemmer zur behandlung von augenkrankheiten
DE60105614D1 (de) Oxazinochinolone für die behandlung viraler infektionen
DE602004023721D1 (de) Zusammensetzungen und methoden für die behandlung von herzerkrankungen
DE60236743D1 (de) Zur behandlung androgenabhängiger krankheiten
DE50105735D1 (de) Chlorzoxazon zur behandlung von psoriasis
ATE333872T1 (de) Zusammensetzng auf diclofenac-basis für die topische behandlung von erkrankungen des oropharynx
DE60201440D1 (de) Aryl-8-azabicyclo[3.2.1]octanes für die behandlung von depression
ATE391507T1 (de) S-methyl-dihydro-ziprasidone für die behandlung von schizophrenie

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1448205

Country of ref document: EP